Modality
Small Molecule
MOA
FXIai
Target
BTK
Pathway
RAS/MAPK
NMOSDPAHHCC
Development Pipeline
Preclinical
~Mar 2016
→ ~Jun 2017
Phase 1
Sep 2017
→ Apr 2025
Phase 1Current
NCT08847344
2,708 pts·PAH
2017-09→2025-04·Terminated
2,708 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-04-0112mo agoInterim· PAH
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2
P1
Termina…
Catalysts
Interim
2025-04-01 · 12mo ago
PAH
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08847344 | Phase 1 | PAH | Terminated | 2708 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| RHH-8482 | Roche | Phase 1 | BTK | |
| NVS-6360 | Novartis | Approved | CD38 | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| Semazasiran | BeiGene | Phase 1 | PD-1 |